Rijen, Netherlands

Niels Hoogenboom



Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 6(Granted Patents)


Location History:

  • Ryen, NL (2014 - 2015)
  • Rijen, NL (2020 - 2021)

Company Filing History:


Years Active: 2014-2021

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Niels Hoogenboom: Innovator in Pharmaceutical Chemistry

Introduction

Niels Hoogenboom is a notable inventor based in Rijen, Netherlands. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds for therapeutic applications. With a total of four patents to his name, Hoogenboom's work focuses on addressing various medical disorders.

Latest Patents

Among his latest patents, Niels Hoogenboom has developed imidazopyrazine inhibitors of Bruton's tyrosine kinase (BTK). These inventions relate to BTK inhibitors or pharmaceutically acceptable salts, cocrystals, esters, prodrugs, solvates, hydrates, or derivatives thereof. The pharmaceutical compositions comprising these compounds are intended for use in therapy, particularly for treating hyperproliferative disorders, inflammatory disorders, immune disorders, or autoimmune disorders.

Career Highlights

Throughout his career, Niels Hoogenboom has worked with prominent companies in the pharmaceutical industry, including Merck Sharp & Dohme B.V. and Acerta Pharma B.V. His experience in these organizations has allowed him to contribute to the advancement of medical treatments through innovative research and development.

Collaborations

Niels Hoogenboom has collaborated with several professionals in his field, including Tjeerd Barf and Arthur A. Oubrie. These collaborations have further enriched his work and have led to the development of impactful pharmaceutical solutions.

Conclusion

Niels Hoogenboom stands out as an influential inventor in the realm of pharmaceutical chemistry. His innovative patents and collaborations reflect his commitment to advancing medical science and improving therapeutic options for patients.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…